Literature DB >> 17266573

Towards better brain management: nootropics.

Ruchi Malik1, Abhijeet Sangwan, Ruchika Saihgal, Dharam Paul Jindal, Poonam Piplani.   

Abstract

The learning and memory deficits have been recognized as severe and consistent neurological disorders associated with numerous neurodegenerative states. Research in this area has gained momentum only in the recent past after the biochemical and physiological basis of these processes have been understood. A considerable alteration in the neurotransmission is a consistent finding in cognitive disorders. Therefore, many therapeutic strategies to augment the concentration of neurotransmitters in brain such as cholinergic agents, biogenic amines and neuropeptides etc. have been evaluated in cognitive deficits. CNS modulators are the type of antiamnesics that act via modulation of the neurological processes underlying memory storage. These include psychostimulants, excitatory amino acids and most important of all "nootropics". Nootropics are a heterogeneous group of compounds of diverse chemical composition and biological function that allegedly facilitate learning and memory or overcome natural or induced cognitive impairments. The literature survey incorporated in this article hallmarks the success achieved in the design and development of potential nootropic agents. Additionally, this review is an attempt towards discussing various approaches available to enhance memory, along with the classification of the known memory enhancers, authors research work towards various structural modifications carried out and the biological screening.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266573     DOI: 10.2174/092986707779313408

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  7 in total

1.  A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Alexander Tsodikov; Jeanna Millman; Heather Bentley; Ben Gouaux; Scott Fishman
Journal:  J Pain       Date:  2008-04-10       Impact factor: 5.820

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

3.  Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam.

Authors:  Kristina Leuner; Christopher Kurz; Giorgio Guidetti; Jean-Marc Orgogozo; Walter E Müller
Journal:  Front Neurosci       Date:  2010-09-07       Impact factor: 4.677

4.  Aniracetam does not improve working memory in neurologically healthy pigeons.

Authors:  Hannah Phillips; Arlene McDowell; Birgitte S Mielby; Ian G Tucker; Michael Colombo
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

Review 5.  Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs.

Authors:  Matěj Malík; Pavel Tlustoš
Journal:  Nutrients       Date:  2022-08-17       Impact factor: 6.706

Review 6.  Clinical pharmacology and pharmacokinetics of levetiracetam.

Authors:  Chanin Wright; Jana Downing; Diana Mungall; Owais Khan; Amanda Williams; Ekokobe Fonkem; Darin Garrett; Jose Aceves; Batool Kirmani
Journal:  Front Neurol       Date:  2013-12-04       Impact factor: 4.003

7.  Designing a Formulation of the Nootropic Drug Aniracetam Using 2-Hydroxypropyl-β-Cyclodextrin Suitable for Parenteral Administration.

Authors:  Sebastian D Goldsmith; Arlene McDowell
Journal:  Pharmaceutics       Date:  2018-11-18       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.